Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.

Takahari, Daisuke; Nakayama, Izuma

Takahari, Daisuke; Nakayama, Izuma.

Affiliation

Takahari D; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan. daisuke.takahari@jfcr.or.jp.
Nakayama I; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.

Int J Clin Oncol ; 28(11): 1431-1441, 2023 Nov.

Article in En | MEDLINE | ID: mdl-37500970

Subject(s)

Esophageal Neoplasms; Stomach Neoplasms; Humans; Immune Checkpoint Inhibitors/therapeutic use; Stomach Neoplasms/drug therapy; Stomach Neoplasms/surgery; Stomach Neoplasms/pathology; Esophagogastric Junction/surgery; Esophagogastric Junction/pathology; Esophageal Neoplasms/drug therapy; Esophageal Neoplasms/surgery; Esophageal Neoplasms/pathology; Fluorouracil/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Key words

Esophageal cancer; Gastric cancer; Gastroesophageal junction cancer; Immune checkpoint inhibitor; Perioperative therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms Language: En Journal: Int J Clin Oncol Year: 2023 Type: Article Affiliation country: Japan

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google